Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to -$42.4 million.

  • UroGen Pharma's Free Cash Flow fell 5258.29% to -$42.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$138.1 million, marking a year-over-year decrease of 4331.44%. This contributed to the annual value of -$97.1 million for FY2024, which is 2676.11% down from last year.
  • Per UroGen Pharma's latest filing, its Free Cash Flow stood at -$42.4 million for Q3 2025, which was down 5258.29% from -$40.0 million recorded in Q2 2025.
  • UroGen Pharma's 5-year Free Cash Flow high stood at -$13.1 million for Q4 2023, and its period low was -$42.4 million during Q3 2025.
  • For the 5-year period, UroGen Pharma's Free Cash Flow averaged around -$24.8 million, with its median value being -$23.8 million (2024).
  • As far as peak fluctuations go, UroGen Pharma's Free Cash Flow skyrocketed by 4003.22% in 2023, and later plummeted by 6769.89% in 2025.
  • Over the past 5 years, UroGen Pharma's Free Cash Flow (Quarter) stood at -$20.3 million in 2021, then decreased by 7.36% to -$21.8 million in 2022, then skyrocketed by 40.03% to -$13.1 million in 2023, then dropped by 5.23% to -$13.7 million in 2024, then crashed by 208.41% to -$42.4 million in 2025.
  • Its last three reported values are -$42.4 million in Q3 2025, -$40.0 million for Q2 2025, and -$42.1 million during Q1 2025.